Clinical Trial Update: A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II trial of Anti-KIR in smoldering multiple myeloma was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Anti-KIR

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma, Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2015-05-15